PA
NGNE icon

Parallel Advisors’s Neurogene NGNE Stock Holding History

Parallel Advisors’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.94K Buy
+96
New +$1.86K ﹤0.01% 3386
2021
Q4 		– Sell
-3
Closed – – 3217
2021
Q3 		$0 Buy
+3
New +$459 ﹤0.01% 3204

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Parallel Advisors's NGNE Position: Q1 2026 in Review

Parallel Advisors opened a new position in Neurogene (NGNE) in Q1 2026: 96 shares worth $1.94K. The stake represents ﹤0.01% of the portfolio and ranks #3386 among its holdings. This is a return to the name: Parallel Advisors previously reported a position in NGNE as recently as Q3 2021.

Parallel Advisors first reported a position in NGNE in Q3 2021 and has held it in 2 quarters since. 96 funds tracked by Wall St. Rank hold NGNE as of Q1 2026.

  • Parallel Advisors held 96 shares of Neurogene worth $1.94K as of Q1 2026.
  • Neurogene was a new Parallel Advisors position in Q1 2026.
  • Neurogene made up ﹤0.01% of Parallel Advisors's portfolio in Q1 2026, its #3386 holding.
  • Parallel Advisors first reported a position in Neurogene in Q3 2021 and has held it in 2 quarters since.
  • 96 funds tracked by Wall St. Rank held Neurogene as of Q1 2026.

Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.